MedTrace Logo

Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

NCT00630409 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2017-03-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the hypothesis that the combination of gemcitabine and doxil will have clinical activity in patients with metastatic renal cell carcinoma.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Gemcitabine

800 mg IV day 1 and 8

DRUG

Doxil

24 mg/m2 every 21 days IV

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Leonard J Appleman, MD, PhD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00630409 on ClinicalTrials.gov